Evommune Inc Dossier - Source-backed chat

Evommune Inc

EVMNNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $261.7M

Enterprise Value $50.2M

Shares Outstanding 36M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Evommune, Inc. (NYSE: EVMN) is a highly promising clinical-stage biotechnology company targeting massive markets in chronic inflammatory diseases, specifically atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). The company's strategy of in-licensing clinically validated, deprioritized assets from large pharma and advancing them through focused Phase 2 trials significantly compresses development timelines and mitigates early-stage discovery risks. Backed by a stellar management team with a proven track record of successful exits (e.g., Dermira's $1.1B sale to Eli Lilly) and a robust cash runway extending through 2028, Evommune is well-positioned to deliver multiple high-impact clinical catalysts in 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$27.57

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

EVO756 fails to show statistically significant improvement in UAS7 in the Phase 2b CSU trial, or exhibits unexpected safety concerns that halt development. EVO301's subcutaneous formulation fails to replicate the strong efficacy seen in the intravenous Phase 2a trial. The lack of positive clinical catalysts forces the company to rely on highly dilutive capital raises, severely contracting the stock price.

Base CaseCentral scenario

$30.0050%

EVO756 meets its primary endpoints in the Phase 2b CSU trial with a competitive efficacy and safety profile, validating the MRGPRX2 pathway. EVO301 successfully transitions into a Phase 2b subcutaneous trial following positive Phase 2a proof-of-concept data. The company maintains its cash runway through 2028, allowing it to advance its pipeline systematically without immediate dilutive financing pressures.

Bull CaseUpside scenario

$45.0030%

EVO756 delivers outstanding Phase 2b results in CSU and AD, establishing it as a best-in-class oral MRGPRX2 antagonist. Concurrently, EVO301's subcutaneous formulation shows superior efficacy and safety in Phase 2b, positioning it as a viable competitor to blockbuster biologics like Dupixent. Strong clinical data triggers a lucrative co-development partnership with a major pharmaceutical company, providing non-dilutive funding and driving the stock price significantly higher.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked clinical pipeline through strategic in-licensing of assets with established Phase 1 safety profiles.
Strong Phase 2a proof-of-concept data for EVO301 in atopic dermatitis, showing a 33% placebo-adjusted EASI improvement.
Robust balance sheet with $307 million in cash, cash equivalents, and investments as of Q1 2026, providing runway through 2028.
Highly experienced leadership team with a history of successful drug development and multi-billion dollar biopharma exits.

Key Investment Risks

High binary clinical trial risk, with major Phase 2b readouts for lead asset EVO756 expected in mid-to-late 2026.
Intense competitive landscape in atopic dermatitis and urticaria, dominated by established blockbusters like Dupixent.
Capital-intensive nature of late-stage clinical development, which will require substantial future funding for Phase 3 trials.

Thesis Invalidation Triggers

Failure of EVO756 to meet its primary efficacy endpoint in the Phase 2b CSU trial.
Safety or tolerability issues arising in ongoing clinical trials that lead to FDA clinical holds.
Inability to successfully formulate or deliver the subcutaneous version of EVO301 with comparable efficacy to the IV formulation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.